Tissue Regenix Group - Additional manufacturing capacity secured
Additional manufacturing capacity secured as part of expansion strategy
The new facility, situated on adjacent land to the Group's current 13,700 sq. ft. facility, will be brought on stream in a phased plan to meet the growing commercial demand for the Company's novel product portfolio. Phase one will commence immediately with part of the new building being converted into office, distribution and warehouse space, allowing for additional clean rooms to be built in the original facility, which are expected to be operational by the end of H1 2020.
Over time, it is planned for further processing and packaging clean rooms to be built in the new facility therefore, increasing the Company's ability to process more tissue and produce products. The new facility underpins the Company's strategy of building strategic partnerships, accelerating US market penetration and pursuing geographic expansion opportunities.
"I am delighted that we have secured this additional facility to support our ambitious growth plans. The Group has undertaken a number of operational initiatives in order to increase production capabilities and meet the growing market demand for our products. Having commenced a second shift at the beginning of the year in our current facility in
For more Information:
| || |
Tel: 0330 430 3073 / 07920272441
| || |
Tel: 0207 710 7600
Tel: 0203 727 1000
This information is provided by RNS, the news service of the
Quick facts: Tissue Regenix Group PLC
Market Cap: £4.92 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE